Ambit Biosciences Corporation Revenue and Competitors
Estimated Revenue & Valuation
- Ambit Biosciences Corporation's estimated annual revenue is currently $43.1M per year.
- Ambit Biosciences Corporation's estimated revenue per employee is $155,000
Employee Data
- Ambit Biosciences Corporation has 278 Employees.
- Ambit Biosciences Corporation grew their employee count by 19% last year.
Ambit Biosciences Corporation's People
| Name | Title | Email/Phone |
|---|
Ambit Biosciences Corporation Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Ambit Biosciences Corporation?
Ambit Biosciences is combining the power of our KINOMEscanâ„¢ kinase profiling technology with an innovative licensing strategy and a history of kinase expertise to discover, optimize and advance a sustainable pipeline of small molecule kinase inhibitors for the treatment of cancer.
keywords:N/A
N/A
Total Funding
278
Number of Employees
$43.1M
Revenue (est)
19%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Ambit Biosciences Corporation News
Ambit Biosciences Corporation, Celgene Corporation, Cephalon, Clavis Pharma, Eisai, Genzyme Corporation, Sunesis Pharmaceuticals.
... Market Size, Share, Growth 2022-2029| Key Players Ambit Biosciences Corporation, Celgene Corporation, Cephalon, Clavis Pharma.
(5)Member of the Nominating and Corporate Governance Committee ... served as Chairman of the Board of Ambit Biosciences Corporation,...
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $88.7M | 278 | -54% | N/A |
#2 | $77.7M | 278 | 7% | N/A |
#3 | $88.7M | 278 | 9% | N/A |
#4 | $15M | 278 | 3% | N/A |
#5 | $15M | 278 | 5% | N/A |